Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
about
Acellular vaccines for preventing whooping cough in childrenAcellular vaccines for preventing whooping cough in childrenThe pertussis enigma: reconciling epidemiology, immunology and evolutionPertussis vaccine trials in the 1990sPertussis: Microbiology, Disease, Treatment, and Prevention.Changes in the genomic content of circulating Bordetella pertussis strains isolated from the Netherlands, Sweden, Japan and Australia: adaptive evolution or drift?Acellular pertussis vaccines and the role of pertactin and fimbriae.Resurgence of pertussis calls for re-evaluation of pertussis animal models.Immunization of teenagers with a fifth dose of reduced DTaP-IPV induces high levels of pertussis antibodies with a significant increase in opsonophagocytic activitySeroprevalence of pertussis antitoxin (anti-PT) in Sweden before and 10 years after the introduction of a universal childhood pertussis vaccination program.Licensed pertussis vaccines in the United States. History and current state.Factors contributing to pertussis resurgence.Factors influencing the spread of pertussis in households: a prospective study, Catalonia and Navarre, Spain, 2012 to 2013.Unraveling the challenges of pertussis.Pertussis: a matter of immune modulation.Re-emergence of pertussis: what are the solutions?Pertussis resurgence: waning immunity and pathogen adaptation - two sides of the same coin.Review of a new fully liquid, hexavalent vaccine: Hexaxim.The virulence factors of Bordetella pertussis: talented modulators of host immune response.Protecting Newborns Against Pertussis: Treatment and Prevention Strategies.Immune persistence after pertussis vaccination.Pertussis: History of the Disease and Current Prevention Failure.Accelerating control of pertussis in England and Wales.The Pertussis resurgence: putting together the pieces of the puzzle.Clinical characteristics and pertussis costs in cases reported to epidemiological services and cases detected in household contacts in Catalonia (Spain).Pertussis vaccines: position paper of Indian Academy of Pediatrics (IAP).The UK pertussis epidemic: implications for immunisation.Efficacy and effectiveness of acellular pertussis vaccines: a 20-year Swedish experience.Time since last vaccine dose in PCR-positive and PCR-negative children with suspected pertussis to monitor pertussis vaccine effectiveness.Antibody responses to defined regions of the Bordetella pertussis virulence factor pertactin.DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™): a guide to its use in infants.PertussisPerformance of the new clinical case definitions of pertussis in pertussis suspected infection and other diagnoses similar to pertussis
P2860
Q24193554-D096680D-0EA0-4919-B1A1-591FFA1ADA2CQ24201103-DE252B30-80D4-43C2-8CBE-10F41FF64771Q26772095-0CFDD435-96DE-4613-B1F9-00AEFD6B8C0BQ27025393-36CBC09B-7C6A-4DE7-B713-5514B6CE8176Q30251684-2BCECFFE-1A84-4F0F-832D-CFD87725E951Q33526658-29B3CBE7-23DE-4D4D-A068-6DA25320A6A2Q34002283-94113329-2E2C-476B-A164-6FBB8CF4E719Q34311615-AF655A22-2678-4D3B-BDC3-3D5026057D61Q35138820-8D904472-5984-4E3A-B819-5A6B38FA8057Q36189916-DFA00D00-18E9-4552-8E2F-3CAFE5937E7DQ37154787-C912359C-E5CF-456B-8200-CAD85DD5F6C1Q37174125-72A29D30-9CD5-4063-8A0D-78BD16D5D71DQ37485438-95111BF1-8FF7-4411-87D1-5506BB2A6EE0Q37495317-FF13BC69-42C5-4E75-91D8-13BF93099F02Q37825920-A08DAC73-CC0A-49F9-AA0A-9AE23735CF7EQ38068231-3F45DC15-5A3C-4236-8675-407A5BD13E5FQ38081288-874BA9C4-B43F-40A3-B39C-2CE77BFDC54EQ38084695-EEC47875-C51F-411A-9B6E-926ECABDD897Q38129761-89BED123-5DBC-41C5-AAC4-09419B9368F1Q38626455-FD1F20F4-4169-470C-8293-17764CBFD5CDQ38775297-F5719978-2B77-4181-ABCD-14649F7CB6C6Q38852136-52494A6B-F095-4BC7-BA82-AA6645A11EE9Q39662144-B7D5C098-57DC-479B-BE6E-46270362DB59Q40061323-866C8AB4-BFCF-49F9-B3A7-3D89258D5C98Q40156865-E824CD66-D8BF-4CAE-8D23-E85E7AD13DC6Q42234559-6BCAF3F1-1F1F-4421-83BF-9B51ED00FB79Q42244374-E0121FE4-39B6-431C-8B51-861677F0EF70Q44635614-2F7C1E1A-E83C-4FF9-AB08-3E06DD3DFA7BQ44807885-22A1EB91-DAC8-49BA-A523-F6ECF0C6E55AQ44834884-7A88ACC3-E150-4A48-AB50-EFEA215C29EEQ46008302-048CC0FC-42FD-4641-BAB7-0C0545CBA685Q57450944-30E71FAB-AE39-4DD8-AB2D-C9781B8C5E54Q58713556-BCD8E6D9-4392-4B25-AAE9-59EA56C7B76F
P2860
Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh-hant
name
Long-term follow-up of Swedish ...... r dose at 5 to 7 years of age.
@en
Long-term follow-up of Swedish ...... r dose at 5 to 7 years of age.
@nl
type
label
Long-term follow-up of Swedish ...... r dose at 5 to 7 years of age.
@en
Long-term follow-up of Swedish ...... r dose at 5 to 7 years of age.
@nl
prefLabel
Long-term follow-up of Swedish ...... r dose at 5 to 7 years of age.
@en
Long-term follow-up of Swedish ...... r dose at 5 to 7 years of age.
@nl
P2093
P356
P1433
P1476
Long-term follow-up of Swedish ...... r dose at 5 to 7 years of age.
@en
P2093
Jann Storsaeter
Lennart Gustafsson
Luc Hessel
Patrick Olin
P304
P356
10.1542/PEDS.2005-2746
P407
P577
2006-09-01T00:00:00Z